A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient

Abstract

Keywords

alopecia areata alopecia universalis Janus kinase inhibitor Severity of Alopecia Tool tofacitinib

Get full access to this article

View all access options for this article.

References

Villasante Fricke

Miteva

Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403.

Papadopoulos

Schwartz

Janniger

CK.

Alopecia areata: pathogenesis, diagnosis, and therapy. Am J Clin Dermatol. 2000;1(2):101-105.

Craiglow

King

BA.

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988-2990.

Craiglow

Liu

King

BA.

Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29-32.

Gupta

Carviel

Abramovits

Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatology Venereol. 2016;30(8):1373-1378.

Jabbari

Nguyen

Cerise

et al . Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642-643.

Kennedy Crispin

Craiglow

et al . Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.

Liu

Craiglow

Dai

King

BA.

Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22-28.